Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation

Purpose Isocitrate dehydrogenase (IDH) mutations lead to formation of the oncometabolite 2-hydroxyglutarate (2-HG), which is elevated in several solid and liquid tumors. Ivosidenib (AG-120) is a targeted, potent, oral inhibitor of the mutant IDH1 protein. We describe detailed pharmacokinetics and ph...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer chemotherapy and pharmacology Ročník 85; číslo 5; s. 959 - 968
Hlavní autoři:	Fan, Bin, Dai, David, DiNardo, Courtney D., Stein, Eytan, de Botton, Stéphane, Attar, Eyal C., Liu, Hua, Liu, Guowen, Lemieux, Ian, Agresta, Samuel V., Yang, Hua
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2020 Springer Nature B.V
Témata:	Blood cancer Bone marrow Cancer Research Cholesterol Dosage Enzymatic activity IDH1 protein Isocitrate dehydrogenase Medicine Medicine & Public Health Mutation Oncology Original Article Pharmacodynamics Pharmacokinetics Pharmacology/Toxicology Tumors Hematologic malignancies Pharmacokinetics Isocitrate dehydrogenase 2-Hydroxyglutarate Ivosidenib
ISSN:	0344-5704, 1432-0843, 1432-0843
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!